Home

Endotronix has announced that the US Food and Drug Administration (FDA) has granted approval for an amendment to the company’s PROACTIVE-HF study, a pivotal Investigational Device Exemption (IDE) trial investigating the Cordella Pulmonary Artery (PA) Pressure Sensor, shifting the design from a randomised control study to a single-arm study.

Following the 2021 update to the 2017 American College of Cardiology (ACC) Expert Consensus Decision Pathway for Optimization of Heart Failure Treatment and the recently presented GUIDE-HF data, the FDA’s decision underscores the clinical benefits of PA pressure-guided HF management for New York Heart Association (NYHA) class III heart failure patients, Endotronix said in a press release.

“The FDA’s decision to approve the amended study design further validates what we are seeing in clinical practice. PA pressure-guided heart failure management is quickly becoming standard of care for NYHA class III patients based on the growing body of evidence supporting this approach,” commented Liviu Klein (University of California San Francisco, San Francisco, USA) and national principal investigator of the PROACTIVE-HF trial. “Understanding changes in PA pressure data is key to properly implementing guideline directed medical therapy and keeping these patients out of the hospital. The Cordella HF System and Sensor offers the next gen technology in PA pressure sensing and will play a critical part in how heart failure patients are managed moving forward.”

The single-arm study design maintains similar safety and efficacy endpoints as the original study design, with the primary efficacy endpoint designed to demonstrate low rates of all-cause mortality and HF hospitalisations in the high-risk NYHA class III patient cohort.

Under the updated study design, the PROACTIVE-HF trial will enrol over 400 NYHA class III patients at more than 100 sites worldwide. The trial is expected to complete enrolment in the second half of this year.

“The FDA’s decision is great news for our PROACTIVE-HF study patients—they now have immediate access to technology that is designed to keep them healthier and out of the hospital. Furthermore, it is an important acknowledgement for the therapeutic category and the benefits that PA pressure-guided heart failure management enables,” stated Harry Rowland, CEO of Endotronix. “Our team and clinical partners have been energised by the announcement and it obviously has a significant impact on our ability to bring the Cordella Sensor to market sooner in the US and Europe.”

Source CardiovascularNews

Duc Tin Clinic

Chia sẽ qua facebook bài: Endotronix announces FDA approval for PROACTIVE-HF pivotal trial design change

Chia sẽ qua google bài: Endotronix announces FDA approval for PROACTIVE-HF pivotal trial design change

Chia sẽ qua twitter bài: Endotronix announces FDA approval for PROACTIVE-HF pivotal trial design change

Chia sẽ qua MySpace bài: Endotronix announces FDA approval for PROACTIVE-HF pivotal trial design change

Chia sẽ qua LinkedIn bài: Endotronix announces FDA approval for PROACTIVE-HF pivotal trial design change

Chia sẽ qua stumbleupon bài: Endotronix announces FDA approval for PROACTIVE-HF pivotal trial design change

Chia sẽ qua icio bài: Endotronix announces FDA approval for PROACTIVE-HF pivotal trial design change

Chia sẽ qua digg bài: Endotronix announces FDA approval for PROACTIVE-HF pivotal trial design change

Chia sẽ qua yahoo bài: Endotronix announces FDA approval for PROACTIVE-HF pivotal trial design change

Tin tức liên quan

Enrolment reaches midway point in trial of Early Bird bleed monitoring system

Eight-fold increased risk of heart attack seen in patients with subclinical obstructive coronary atherosclerosis

ACC 2023: REVIVED-BCIS-2 results challenge “long-held beliefs” on myocardial viability testing prior to PCI

Blood pressure successfully cut in RADIANCE II ultrasound renal denervation trial

New data examine mortality rates and cardiac damage in early-stage aortic stenosis patients

SUPPORT CONSULTANT

Make an Appointment

I am Nguyen Thanh Sang, born in 1990. Since the examination and treatment at the clinic Duc Tin, I am very grateful to the Doctor for explaining and sharing about my illness. During the treatment time in the clinic I was very caring staff of the clinic. Now my illness has improved in a good way. Expect more and more clinic to be able to save many patients.

I sincerely thank you !. Tel: 0938303275

Huynh Thi Muoi, born in 1940, was examined and treated at Duc Tin Clinic. I am very pleased about how to serve and care patients of the clinic. The doctor is committed to explaining and sharing with the patient.

Huynh Thi Muoi sincerely thank you! Phone number: 0972868746

As I said Duc Tin surgical clinin is where my family trust, hope to visit. Physicians caring, thoughtful, gentle to the patient. Nurses and staff clinic polite, cheerful and thoughtful. This clinic clean, sterile, so I would love to. Tel: +84949914060.

The doctor is very caring, attentive and very gentle nurse, courteous, affable with me. The clinic is clean, comfortable, polite. I enjoyed this faith. Every visit I was very relieved disease. Tel: 0839820792.

I was patient, had to clinics of Dr. Le Duc Tin. I see very conscientious doctor patient care, answer any questions and very dedicated staff from the receptionist to the children tested, nursing. Clinics very clean and spacious. I'm very satisfied. Tel: +841227880829.